From the Q2 2024 update-Daybue
"Canada: NDS accepted for Priority Review, potential approval around year-end 2024"
The priority review period for Health Canada is 180 days from the date of the granting of the improved review process.This means that the approval should occur sometime in October 2024.
Just adds more questions as to why Acadia decided to downgrade Daybue 2024 revenues.Daybue has a lot more data available now based on the US longer term experience enabling a speedy Canadian approval.
Kens
Share Price, page-11445
-
- There are more pages in this discussion • 630 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Add NEU (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
$15.13 |
Change
-0.010(0.07%) |
Mkt cap ! $1.933B | |||
| Open | High | Low | Value | Volume |
| $15.04 | $15.30 | $14.96 | $6.401M | 422.6K |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 1 | 1 | $15.12 |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| $15.16 | 6015 | 1 |
View Market Depth
| Last trade - 16.10pm 01/10/2024 (20 minute delay) ? |
| NEU (ASX) Chart |